.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
Recent clinical data suggests that lenvatinib plus pembrolizumab efficacy extends to difficult-to-treat nonendometrioid endometrial cancers. A retrospective study at Jichi Medical University Hospital evaluated clinical outcomes for patients with recurrent disease. Specifically, researchers examined rare variants like carcinosarcoma and mesonephric-like adenocarcinoma. Although these subtypes often carry a poor prognosis, the combination therapy showed meaningful clinical activity.
The study involved 26 patients, including 11 with nonendometrioid carcinoma. Notably, the objective response rate for the nonendometrioid group reached 33.3%. Furthermore, the disease control rate was exceptionally high at 90.9%. In comparison, the endometrioid group had a response rate of 22.2% and a disease control rate of 100%.
Median progression-free survival was 6.2 months for nonendometrioid types. However, patients with endometrioid histology achieved a longer median survival of 11.5 months. In addition, the median overall survival for nonendometrioid cases was 12.0 months. Consequently, these findings highlight the potential of this regimen in managing aggressive histological variants.
Hypertension was the most frequent adverse event, occurring in 92.3% of patients. Moreover, hypothyroidism affected 65.4% of the cohort. As a result, histology and platinum-free intervals were not identified as independent prognostic factors for survival. Therefore, the treatment benefit remains consistent across various clinical subgroups. Further accumulation of patient data is warranted to validate these results in uncommon histologic types.
Research indicates an objective response rate of 33.3% and a disease control rate of 90.9% for nonendometrioid subtypes, including carcinosarcoma and mesonephric-like adenocarcinoma.
The most common adverse events are hypertension, which affects over 90% of patients, and hypothyroidism, seen in approximately 65% of cases.
Disclaimer: This content is for informational and educational purposes only. It is not intended as medical advice or as a substitute for professional healthcare guidance. Refer to the latest local and national guidelines for clinical practice.
References
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
A study reveals the efficacy of lenvatinib plus pembrolizumab for recurrent nonendometrioid endometrial cancer, showing a 33.3% objective response rate....
7 months ago
Novel diimide and hydrazone scaffolds, particularly compound #C4, synergistically reactivate latent HIV-1 when combined with JQ1 or PKC activators. Demonstrating donor-matched proviral transcription ex vivo and non-canonical signaling, these findings advance shock and kill strategies toward reservoir eradication.
Today
A cross-sectional study reveals that maternal RSV vaccination coverage reached only 43.7% in Argentina, with maternal vaccine knowledge being the sole independent predictor of uptake. Clinicians play a crucial role in eliminating informational and structural barriers to optimize infant health.
Today
Review how tailored exercise programs benefit frail older patients with heart failure. Explore pathophysiological mechanisms, individualized training prescriptions, and strategies to overcome adherence barriers in clinical practice.
Yesterday
This comparative study evaluates posterior labral tears with and without glenohumeral instability, highlighting distinct demographic patterns, MRI underestimation in stable shoulders, and successful arthroscopic repair outcomes.
Yesterday
A clinical study demonstrates that early intervention with tocilizumab, either as monotherapy or bridged with corticosteroids, achieves significant proptosis reduction and resolves active inflammation in treatment-naive thyroid eye disease.
Yesterday
